• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

ABT-239 Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754466

ABT-239 is a novel, highly efficacious, non-imidazole class of H3R antagonist. Its a transient receptor potential vanilloid type 1 (TRPV1) antagonist. More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
ABT-239, Inhibitor
Full Product Name
ABT-239
Product Gene Name
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
330.42
Solubility
DMSO: 100mg/mL (302.65mM)
H2O: <0.1mg/mL (insoluble)
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C22H22N2O
SMILES
C[C@H]1N(CCC2=CC3=C(C=CC(C4=CC=C(C#N)C=C4)=C3)O2)CCC1
CAS Number
460746-46-7
Target & IC50
Others
In Vitro
ABT-239 (3mg/kg, i.p.) significantly delays onset of seizure, reduces behavioral seizures elicited by KA, and reduces in the incidence of head bobbing and forelimb clonus in mice. ABT-239 (3mg/kg, i.p.) administration transforms a short-term learning event into a long-term remembered experience in WT but not in histamine-depleted mice[2]. ABT-239 (3mg/kg, i.p.) causes enhanced reduction in all the stages. ABT-239 (3mg/kg, i.p.) and TDZD-8 (10mg/kg, i.p.) have more powerful reduction in the number of pyknotic neurons in mice hippocampi. ABT-239 (1mg/kg, i.p.) in conbination with sub-therapeutic dose of SVP (150mg/kg, i.p.), significantly decreases the number of immobility, head bobbing and forelimb clonus, where as a higher dose combination of The high dose combination of ABT-239 and TDZD-8 produces the most pronounced increase in Bcl-2 expression as well as decrease in the level of Bax[1]. Concomitant administration of either ABT-239 (1 and 3mg/kg, i.p.) and nicotine (0.035mg/kg, i.p.), or ABT-239 (0.1mg/kg, i.p.) and nicotine (0.0175mg/kg, i.p.) further increases nicotine-induced improvement in both memory acquisition and consolidation[3].

Structure of ABT-239, inhibitor

ABT-239 Inhibitor – Cat# MBS5754466

Product References and Citations for ABT-239, inhibitor

Bhowmik M, et al. histamine H receptor antagonism by ABT-239 attenuates kainic acid induced excitotoxicity in mice. Brain Res. 2014 Sep 18;1581:129-40.
Bhowmik M, et al. histamine H receptor antagonism by ABT-239 attenuates kainic acid induced excitotoxicity in mice. Brain Res. 2014 Sep 18;1581:129-40.
Provensi G, et al. Donepezil, an acetylcholine esterase inhibitor, and ABT-239, a histamine H receptor antagonist/inverse agonist, require the integrity of brain histamine system to exert biochemical and procognitive effects in the mouse. Neuropharmacolo
Provensi G, et al. Donepezil, an acetylcholine esterase inhibitor, and ABT-239, a histamine H receptor antagonist/inverse agonist, require the integrity of brain histamine system to exert biochemical and procognitive effects in the mouse. Neuropharmacolo
Kruk M, e tal. Effects of the histamine H receptor antagonist ABT-239 on cognition and nicotine-induced memory enhancement in mice. Pharmacol Rep. 2012;64(6):1316-25.
Kruk M, e tal. Effects of the histamine H receptor antagonist ABT-239 on cognition and nicotine-induced memory enhancement in mice. Pharmacol Rep. 2012;64(6):1316-25.
Munari L, et al. Selective brain region activation by histamine H receptor antagonist/inverse agonist ABT-239 enhances acetylcholine and histamine release and increases c-Fos expression. Neuropharmacology. 2013 Jul;70:131-40.
Munari L, et al. Selective brain region activation by histamine H receptor antagonist/inverse agonist ABT-239 enhances acetylcholine and histamine release and increases c-Fos expression. Neuropharmacology. 2013 Jul;70:131-40.

Other Notes

Small volumes of ABT-239, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for ABT-239 purchase

MBS5754466 is an inhibitor targeting ABT-239.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000